ATB Therapeutics Secures €54 Million for Innovative Therapeutics Development
Deal News | Nov 18, 2024 | PR Newswire Cision EQT
EQT Life Sciences, as part of its LSP 7 fund, announced its co-lead investment in a €54 million Series A funding round for ATB Therapeutics. The round aims to boost the clinical development of ATB's pioneering therapeutic antibodies, engineered using the proprietary ATBioFarm platform. The platform supports the scalable and swift production of novel biologics, integrating enzymatic functionalities for enhanced safety and effectiveness compared to traditional antibodies. This funding round also names MRL Ventures Fund, V-Bio, VIVES Partners, and several other investors as contributors. The financing will facilitate ATB's expansion of research and manufacturing capabilities in Ghent and Marche-en-Famenne. Mark Throsby, former CSO of Merus, joins ATB as Executive Chairman, bringing extensive expertise to the company's leadership. The investment highlights significant progress in the field of oncology and immunology therapeutics, casting ATB as a frontrunner in next-generation biologics.
Sectors
- Biotechnology
- Healthcare
- Private Equity and Venture Capital
Geography
- Belgium – ATB Therapeutics is advancing its operations in Ghent and Marche-en-Famenne, Belgium.
- Sweden – EQT Life Sciences, the leading investor in the funding round, is based in Stockholm, Sweden.
- United States – MRL Ventures Fund, a co-leader of the funding round, is associated with Merck & Co., Inc., located in Rahway, New Jersey.
Industry
- Biotechnology – The article focuses on ATB Therapeutics, a company specializing in biopharmaceuticals, specifically developing antibody-based therapeutics using innovative technologies.
- Healthcare – ATB Therapeutics aims to contribute to the fields of oncology and immunology, which are pivotal areas within the healthcare sector.
- Private Equity and Venture Capital – The involvement of EQT Life Sciences and MRL Ventures Fund in the Series A financing round is notable for private equity and venture capital interests.
Financials
- €54 million – The total amount secured in the Series A funding round for ATB Therapeutics.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| ATB Therapeutics | Target | Company | A biotech company focused on developing innovative therapeutic antibodies for oncology and immunology. |
| EQT Life Sciences | Bidding Company | Company | A private equity company that co-led the €54 million Series A funding for ATB Therapeutics. |
| MRL Ventures Fund | Bidding Company | Company | Corporate venture arm of Merck & Co., Inc., co-leading the funding round. |
| V-Bio Ventures | Investor | Company | A venture capital firm participating in the funding. |
| VIVES Partners | Investor | Company | A contributor to the Series A funding round. |
| SFPIM | Investor | Government | The Belgian sovereign fund involved in the investment. |
| Wallonie Entreprendre | Investor | Government | A Belgian government agency supporting regional entrepreneurship. |
| Sambrinvest | Investor | Company | A regional investment fund from Belgium participating in the funding. |
| Mark Throsby | Executive Chairman | Person | An industry veteran who previously served as Chief Scientific Officer of Merus. |
| Bertrand Magy | CEO | Person | CEO and co-founder of ATB Therapeutics. |
| John de Koning | Board Member | Person | Partner at EQT and a key participant in ATB Therapeutics. |
| Karin Kleinhans | Board Member | Person | Partner at MRLV and part of the Board of Directors at ATB Therapeutics. |